Open AccessToward Orally Absorbed Prodrugs of the Antibiotic Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part 2
Author(s) -
Eric M. Gordon,
Matthew A. J. Duncton,
Brian J Wang,
Longwu Qi,
Dazhong Fan,
Xianfeng Li,
ZhiJie Ni,
Pingyu Ding,
Ruslan Grygorash,
Eddy Low,
Guijun Yu,
Jiawei Sun
Publication year - 2020
Publication title -
acs medicinal chemistry letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 66
ISSN - 1948-5875
DOI - 10.1021/acsmedchemlett.9b00534
Subject(s) - aztreonam , prodrug , antibiotics , pharmacology , bioavailability , medicine , pharmacokinetics , chemistry , biochemistry , antibiotic resistance , imipenem
Aztreonam, first discovered in 1980, is an FDA approved, intravenous, monocyclic beta-lactam antibiotic. Aztreonam is active against Gram-negative bacteria and is still used today. The oral bioavailability of aztreonam in humans is less than 1%. Herein we describe the design and synthesis of potential oral prodrugs of aztreonam.